Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in
the treatment of choroidal neovascularization in underlying angioid streaks due to
Pseudoxanthoma elasticum. 10 patients will receive monthly injections of the drug in one eye
over a period of one year.